Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonist

Discovery and background

Retatrutide — development code LY3437943, assigned by Eli Lilly — entered human clinical trials in 2021, marking the first time a single monomeric peptide designed to simultaneously agonise all three of the GIP, GLP-1, and glucagon receptors had been tested in a registered Phase I programme. Its conceptual origins, however, stretch back to foundational academic work completed several years earlier.

The intellectual blueprint for triple-receptor peptide agonism was laid out by Finan, Tschöp, DiMarchi, and colleagues in a landmark 2015 Nature Medicine paper demonstrating that a rationally designed triagonist peptide corrected obesity and metabolic dysfunction in rodents more completely than dual or single agonists alone [PMID:25485909]. That proof-of-concept established the principle that simultaneously engaging all three receptor arms of the incretin-glucagon axis produced additive or synergistic metabolic benefit, and it catalysed pharmaceutical industry programmes aimed at translating the concept into a clinically viable molecule.

Eli Lilly's medicinal chemistry team addressed the principal challenge of triagonist design — achieving balanced, sustained activity at three structurally divergent receptors without unacceptable selectivity bias or short plasma half-life — by building on the fatty-acid conjugation strategy already validated by tirzepatide. Retatrutide is a modified 39-amino-acid peptide conjugated to a C18 fatty-diacid moiety via a hydrophilic linker, enabling albumin binding that extends its plasma half-life to approximately six days and supports once-weekly subcutaneous administration [PMID:36257318]. First-in-human pharmacokinetic and tolerability data were published in The Lancet in 2022, confirming the predicted half-life, dose-proportional exposure, and an acceptable initial safety signal that justified Phase II advancement [PMID:36356612].

Mechanism of action

Retatrutide exerts its metabolic effects by acting as a full or partial agonist at three distinct G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Each receptor arm contributes a distinct physiological response, and their simultaneous activation produces a composite metabolic effect that appears to exceed what any two-receptor combination achieves alone.

GLP-1 receptor agonism drives the greatest component of glucose-lowering and appetite suppression. GLP-1R engagement in pancreatic beta cells potentiates glucose-stimulated insulin secretion in a glucose-dependent manner — meaning hypoglycaemia risk is substantially lower than with exogenous insulin — while GLP-1R signalling in the hypothalamus, brainstem, and vagal afferents reduces appetite and delays gastric emptying [PMID:34626850]. Slowed gastric transit contributes to postprandial satiety and is also the primary driver of the GI tolerability challenges associated with this drug class.

GIP receptor agonism complements GLP-1R activity in several ways. In isolation, GIP has modest insulinotropic and glucagonotropic effects, but in combination with GLP-1R agonism, GIPR co-activation appears to amplify incretin-mediated insulin release, potentiate central appetite suppression, and — critically — reduce the nausea burden associated with pure GLP-1R agonism [PMID:36257318]. The attenuated nausea profile may partly explain why retatrutide subjects in Phase II trials were able to reach and maintain higher therapeutic doses compared with historical GLP-1 monotherapy cohorts.

Glucagon receptor agonism is the novel mechanistic element that distinguishes retatrutide and related triagonists from the dual GIP/GLP-1 class exemplified by tirzepatide. Glucagon is classically regarded as a catabolic, hyperglycaemic hormone, and its co-administration might appear counterproductive in a glucose-lowering programme. However, carefully balanced GCGR agonism in the context of simultaneous GLP-1R activation yields net metabolic benefit: glucagon drives thermogenesis in brown adipose tissue, upregulates hepatic fatty acid oxidation, and increases resting energy expenditure — effects that have been demonstrated in human infusion studies [PMID:23274906]. The net result is enhanced fat mobilisation and calorie burning over and above what appetite suppression alone can achieve. Eli Lilly calibrated the relative receptor selectivity of retatrutide to provide meaningful but not hyperglycaemia-inducing glucagon activity, relying on GLP-1-mediated insulin secretion to offset GCGR-driven glucose output [PMID:36257318].

Researched applications

Retatrutide has been studied in two pivotal Phase II randomised controlled trials — one in adults with obesity or overweight (non-diabetic), and one in adults with type-2 diabetes — both published in 2023.

Phase II obesity trial (PMID:37366315). The trial enrolled 338 adults with a body-mass index of at least 27 kg/m² who did not have diabetes. Participants were randomised to once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg (the latter two with different titration schedules), or to placebo, for 48 weeks. The primary endpoint was percentage change in body weight from baseline to week 24. At 48 weeks — the key secondary endpoint — the 12 mg high-dose cohort achieved a mean body-weight reduction of 24.2%, with a substantial proportion of participants reaching reductions exceeding 15% and 20% of initial body weight. These figures represent the largest mean weight loss reported in any randomised controlled trial of a single peptide therapeutic as of the time of publication, surpassing the approximately 20% achieved with semaglutide (STEP-1) and the approximately 21% with tirzepatide (SURMOUNT-1) in comparable populations.

Phase II type-2 diabetes trial (PMID:37480976). A parallel Lancet-published trial enrolled adults with type-2 diabetes inadequately controlled on metformin with or without other oral agents. Retatrutide demonstrated robust HbA1c reductions — up to 2.2 percentage points from a mean baseline of approximately 8.3% — alongside weight loss of approximately 16% at the highest doses over 36 weeks, substantially exceeding the glycaemic and weight outcomes of established comparators in this population.

The magnitude of the obesity trial result prompted considerable scientific interest, with commentary in Nature Medicine and Lancet Diabetes & Endocrinology contextualising retatrutide as a potential step-change in pharmacological weight management rather than an incremental advance. Phase III trials (TRIUMPH programme) commenced enrolment in 2024 and are ongoing as of May 2026, evaluating retatrutide in larger and more diverse populations including subjects with cardiovascular disease, chronic kidney disease, and sleep apnoea.

Dosing

All dosing information below is drawn from published Phase II clinical trial protocols and is presented for scientific and informational purposes only. Retatrutide is not approved for therapeutic use in any jurisdiction as of May 2026.

The Phase II obesity trial employed a structured titration schedule designed to build GI tolerance before advancing to target doses. The titration approach used in the highest-dose group proceeded approximately as follows: participants began at a starting weekly dose of 2 mg subcutaneously for the first four weeks, then advanced stepwise — generally doubling or increasing by 2 mg increments at intervals of four to eight weeks — with the goal of reaching a maintenance dose of 12 mg/week by around week 24. Total trial duration was 48 weeks, providing approximately 24 weeks at or near maintenance dose. Lower-dose cohorts in the trial (4 mg and 8 mg maintenance) followed proportionally compressed titration schedules.

The starting dose of 2 mg/week was selected based on Phase I pharmacodynamic data suggesting that lower doses were sufficient to initiate GI adaptation while producing modest early weight loss [PMID:36356612]. Dose escalation was conducted under medical supervision in the trial context; investigators held or adjusted doses in participants experiencing intolerable GI adverse events.

Once-weekly dosing reflects the approximately six-day half-life conferred by the fatty-acid/albumin-binding conjugation strategy. Injections were administered to the abdomen, thigh, or upper arm in a rotating-site pattern consistent with standard subcutaneous peptide injection protocols.

Safety profile

The safety data from Phase II trials present a coherent picture consistent with the GLP-1R agonist class, with some modifications attributable to the glucagon receptor component.

Gastrointestinal tolerability. Nausea, vomiting, diarrhoea, and decreased appetite were the most frequently reported adverse events, predominantly occurring during dose escalation [PMID:37366315]. Approximately one-third of participants in the highest-dose cohort experienced nausea, with the majority of episodes graded mild to moderate and resolving with continued dosing as GI adaptation occurred. The GI tolerability profile was broadly comparable to tirzepatide at equivalent weight-loss doses, and notably better than expected for the level of weight loss achieved — consistent with the hypothesis that GIPR co-agonism attenuates GLP-1-mediated nausea.

Cardiovascular signals. A modest increase in resting heart rate — approximately 5–7 beats per minute above baseline — was observed across retatrutide dose groups, a finding shared by the broader GLP-1R agonist class and attributed to sympathetic activation via GLP-1 and possibly glucagon receptors. No clinically significant arrhythmias were recorded.

Fasting glucose in non-diabetic subjects. A mildly elevated fasting plasma glucose level was noted in some non-diabetic retatrutide participants during the trial, a signal plausibly attributable to GCGR agonism driving hepatic glucose output [PMID:37366315]. The elevation was modest, did not meet criteria for new-onset diabetes in the majority of cases, and was offset by GLP-1-driven insulin secretion, but it represents a metabolic parameter requiring monitoring in longer-duration Phase III evaluation.

Medullary thyroid carcinoma and MEN-2 class warning. In common with all GLP-1 receptor agonists, retatrutide carries a class-level concern regarding rodent studies demonstrating C-cell hyperplasia and medullary thyroid carcinoma (MTC) at supratherapeutic doses. This finding has not been replicated in human or non-human primate data, but the class labelling convention for GLP-1R agonists includes a boxed warning recommending that the drug not be used in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN-2). This warning is expected to apply to retatrutide upon any future regulatory approval.

Injection-site reactions. Mild, self-limiting erythema or pruritus at the injection site was reported in a minority of participants across dose groups, consistent with standard subcutaneous peptide administration.

UK regulatory status 2026

Retatrutide is not approved as a medicinal product in the United Kingdom. It holds no Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), and no Investigational Medicinal Product Dossier has been publicly granted for commercial supply within Great Britain or Northern Ireland. The ongoing Phase III TRIUMPH programme is being conducted under appropriate regulatory frameworks in participating countries, but the UK is not among the primary trial territories for all substudies.

As an unapproved investigational compound, retatrutide cannot lawfully be sold, supplied, or administered to humans in the UK for therapeutic, aesthetic, or any other medicinal purpose under the Human Medicines Regulations 2012. Research-grade retatrutide supplied for in vitro laboratory use — strictly within accredited laboratory settings and not administered to humans or animals — is not subject to the Human Medicines Regulations, provided institutional governance and research ethics requirements are satisfied.

The MHRA's enforcement focus, as communicated in successive advisory statements, targets the supply and promotion of peptide compounds for human injection outside clinical trial authorisation. Researchers and institutions handling retatrutide should maintain documentation of research purpose, sourcing provenance, and compliance with institutional biosafety protocols.

Reconstitution and storage

Research-grade retatrutide is typically supplied as a white lyophilised powder. Reconstitution should be performed using bacteriostatic water (0.9% benzyl alcohol) to a target concentration of 1 mg/mL, though researchers may adjust concentration depending on study protocol requirements. The diluent should be injected slowly down the side wall of the vial rather than directly onto the powder cake; the vial is then swirled gently — never vortexed or shaken — to minimise peptide aggregation and preserve the fatty-acid conjugate's structural integrity.

Reconstituted solution stored at 2–8°C in a light-protected vial is reported to maintain stability for approximately 28 days. For longer archiving, single-use aliquots should be prepared at the point of reconstitution, frozen at -20°C, and thawed once immediately before use. Repeated freeze-thaw cycles risk hydrolysis of the fatty-acid linker and should be avoided. Lyophilised powder, kept desiccated below 25°C away from light and moisture, maintains integrity for the shelf life specified by the supplying laboratory — typically 24 months from date of manufacture.

Because retatrutide carries the fatty-acid conjugate responsible for albumin binding and extended half-life, it is more susceptible to degradation from elevated temperatures than simple, unconjugated peptides. Cold-chain transport and prompt refrigeration upon receipt are therefore particularly important for maintaining bioactivity of research material.

Frequently asked research questions

How does retatrutide differ from tirzepatide? Tirzepatide is a dual GIP/GLP-1 receptor agonist; retatrutide adds a third receptor arm — glucagon receptor agonism — that specifically increases energy expenditure through thermogenesis and hepatic fatty acid oxidation. The glucagon component is proposed as the primary driver of the additional weight loss seen with retatrutide versus tirzepatide in Phase II, though head-to-head comparative trials have not been completed.

What does "triple agonist" mean in practice? It means the single molecule binds to and activates three distinct receptors simultaneously in a single weekly injection. The molecule is engineered with receptor-activity ratios calibrated to maximise weight and metabolic benefit while limiting the hyperglycaemic risk that unbalanced glucagon receptor activation would otherwise produce [PMID:36257318].

Is the 24% weight loss figure confirmed? The 24.2% mean weight reduction figure derives from the 12 mg high-dose group at 48 weeks in the Jastreboff et al. 2023 NEJM Phase II trial [PMID:37366315]. Phase II trials typically enrol highly selected populations with close monitoring and dietary counselling; real-world or Phase III outcomes may differ. Phase III data are pending as of May 2026.

Why is a glucagon agonist included if glucagon raises blood sugar? The glucagon receptor agonism in retatrutide is balanced against simultaneous GLP-1-mediated insulin secretion such that the net glucose effect is near-neutral in most subjects. The thermogenic and lipolytic benefits of glucagon receptor engagement are preserved while the hepatic glucose output signal is largely counteracted [PMID:23274906]. In practice, a mild fasting glucose elevation was observed in Phase II non-diabetic participants, a finding that Phase III monitoring protocols are specifically designed to characterise at scale.

Can retatrutide be obtained for research in the UK? Research-grade retatrutide may be acquired for in vitro laboratory research purposes from compliant suppliers. It is not legally available for human administration. Any research use must comply with applicable MHRA regulations, institutional ethics approval, and relevant biosafety frameworks.

Is retatrutide suitable for stacking with other metabolic peptides? Within published research, retatrutide has been studied as monotherapy. Its mechanism overlaps substantially with GLP-1 pathway agents, and co-administration with other incretin-class compounds is not supported by safety or efficacy data. Combination research with complementary mechanisms — such as AOD-9604, which acts on adipocyte beta-3 receptors independently of the incretin pathway — represents a theoretically distinct approach that is explored separately in the metabolic stack literature below.

---

Retatrutide appears in the following research stacks on this site: Tirzepatide + Retatrutide + AOD-9604 Metabolic Stack.

Source research-grade Retatrutide

Retatrutide — Triple GIP/GLP-1/Glucagon Receptor Agonist is sold for laboratory and in vitro research use only. UK regulatory status: Phase III ongoing (2026). Unapproved globally as of May 2026. Research-grade material is unapproved for human medicinal use..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk

References

Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.

1. Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6) :514-526 doi:10.1056/NEJMoa2301972 · PMID: 37366315
2. Rosenstock J, Frias JP, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401) :529-544 doi:10.1016/S0140-6736(23)01053-X · PMID: 37480976
3. Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;36(1) :109-122 doi:10.1016/j.cmet.2022.09.002 · PMID: 36257318
4. Finan B, Yang B, Ottaway N, et al.. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. 2015;21(1) :27-36 doi:10.1038/nm.3761 · PMID: 25485909
5. Drucker DJ.. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism. 2022;57 :101351 doi:10.1016/j.molmet.2021.101351 · PMID: 34626850
6. Tan TM, Field BC, McCullough KA, et al.. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62(4) :1131-1138 doi:10.2337/db12-0797 · PMID: 23274906
7. Urva S, Coskun T, Loh MT, et al.. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366) :1869-1881 doi:10.1016/S0140-6736(22)02033-5 · PMID: 36356612